<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="Biotech Unit, AstraZeneca, [5], 0000 0004 0376 1796grid.273406.4Genome Biology Division," exact="New England Biolabs," post="Inc, epub: 2019-1-1pmc-release: 2019-1-1collection: 20191011received: 2018-7-26accepted: 2018-11-29(C) , Open"/>
 <result pre="their facility which had the capacity to screen the entire" exact="AstraZeneca" post="1.3 million compound collection. Results Overview of the primary"/>
 <result pre="were moved into the second fully automated stage (using the" exact="Agilent Technologies" post="BioCel system) involving formaldehyde fixation, DNA staining of the"/>
 <result pre="was based on prior knowledge and experience from both the" exact="AstraZeneca" post="and A·WOL chemistry teams. The final selection was further"/>
 <result pre="from these 9 clusters, samples were sourced either from the" exact="AstraZeneca" post="compound inventory or through re-synthesis. All 18 samples were"/>
 <result pre="to background. Primary HTS triaging Chemists from both A∙WOL and" exact="AstraZeneca" post="triaged the hit compounds from the primary screen, based"/>
 <result pre="microsome and hepatocyte clearance measurements, were generated using the standard" exact="AstraZeneca" post="UK high-throughput platform37,38. Supplementary information LINK Supplementary Data 1"/>
</results>
